Published in J Am Heart Assoc on June 06, 2013
Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the β adrenergic system. Front Physiol (2013) 1.03
The Role of Obesity in the Development of Left Ventricular Hypertrophy Among Children and Adolescents. Curr Hypertens Rep (2016) 0.79
Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network). J Am Heart Assoc (2017) 0.77
Identification of phenotypes at risk of transition from diastolic hypertension to isolated systolic hypertension. J Hum Hypertens (2015) 0.75
Effect of dietary sodium and potassium intake on left ventricular diastolic function and mass in adults≤40 years (from the Strong Heart Study). Am J Cardiol (2015) 0.75
Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. Front Pediatr (2017) 0.75
Hypertension Survey in Italy: Novel Findings from the Campania Salute Network. High Blood Press Cardiovasc Prev (2017) 0.75
Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr (1990) 25.24
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol (1986) 18.40
Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief (2012) 10.88
Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol (1992) 6.51
The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol (1990) 4.89
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
Empirical evaluation of very large treatment effects of medical interventions. JAMA (2012) 3.48
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 2.56
Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation (2008) 2.45
Blood-pressure control in the hypertensive population. Lancet (1997) 2.05
Cardiac markers of pre-clinical disease in adolescents with the metabolic syndrome: the strong heart study. J Am Coll Cardiol (2008) 1.81
Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens (2005) 1.79
Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension (2009) 1.74
Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation (2007) 1.67
Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation (1997) 1.66
Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician? Am J Hypertens (2008) 1.55
Differences between clinical trials and postmarketing use. Br J Clin Pharmacol (2004) 1.54
Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care (2007) 1.42
Prognostic value of the extent of left ventricular hypertrophy and its evolution in the hypertensive patient. J Hypertens (2012) 1.40
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens (2012) 1.37
Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation (1994) 1.20
The use of a telematic connection for the follow-up of hypertensive patients improves the cardiovascular prognosis. J Hypertens (2005) 1.11
Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. Am J Cardiol (2010) 0.99
Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol (1996) 0.98
Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study. J Hypertens (2008) 0.97
Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens (2004) 0.96
Echocardiographic left ventricular mass and electrolyte intake predict arterial hypertension. Ann Intern Med (1991) 0.96
Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens (2001) 0.95
An appraisal of echocardiography as an epidemiological tool. The Strong Heart Study. Ann Epidemiol (2003) 0.93
Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens (2000) 0.90
Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens (2005) 0.90
Myocardial fat infiltration. Am Heart J (1962) 0.89
Left ventricular mass and exercise responses predict future blood pressure. The Muscatine Study. Hypertension (1988) 0.89
Determinants of blood pressure treatment and control in obese people: evidence from the general population. J Hypertens (2012) 0.85
Association of suboptimal blood pressure control with body size and metabolic abnormalities. J Hypertens (2007) 0.84
Identifying needs and opportunities for advancing translational research in cardiovascular disease. Cardiovasc Res (2009) 0.82
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. Nutr Metab Cardiovasc Dis (2009) 0.81
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. Nutr Metab Cardiovasc Dis (2011) 0.78
Sodium, left ventricular mass, and arterial hypertension: is it time to look for a new paradigm? Hypertension (2011) 0.77
Temporal obesity trends in patients undergoing transthoracic echocardiography 2002-2006. Am J Cardiol (2009) 0.77
Does increased blood pressure cause left ventricular hypertrophy or vice versa? Ann Intern Med (1990) 0.76
Regression of LVH or reduction of left ventricular mass? Am J Hypertens (2008) 0.76
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Recommendations for chamber quantification. Eur J Echocardiogr (2006) 11.39
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86
The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15
Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation (2009) 5.82
Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med (2014) 5.11
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol (2007) 4.49
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2005) 4.24
Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Aneurysms of the sinuses of Valsalva. Cardiology (2006) 3.64
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27
Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials (2008) 3.24
Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care (2003) 3.21
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension (2007) 2.94
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90
Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Arch Intern Med (2010) 2.89
Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care (2008) 2.76
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med (2005) 2.68
Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med (2006) 2.68
Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data. Hypertension (2009) 2.58
Cadmium exposure and incident cardiovascular disease. Epidemiology (2013) 2.55
Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol (2008) 2.52
Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. Circulation (2009) 2.49
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43
Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care (2003) 2.40
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation (2006) 2.40
Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension (2004) 2.36
Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care (2007) 2.33
Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum (2009) 2.33
Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res (2008) 2.24
Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am J Epidemiol (2003) 2.20
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J (2007) 2.14
Genetic determinants of lipid traits in diverse populations from the population architecture using genomics and epidemiology (PAGE) study. PLoS Genet (2011) 2.13
Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). Am Heart J (2006) 2.08
Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol (2002) 2.08
Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation (2002) 2.05
A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med (2007) 2.05
Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the Strong Heart Study. J Clin Hypertens (Greenwich) (2011) 2.04
Assessment of the thoracic aorta by multidetector computed tomography: age- and sex-specific reference values in adults without evident cardiovascular disease. J Cardiovasc Comput Tomogr (2008) 2.04
Noakes misses the point. S Afr Med J (2013) 2.04
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01
Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol (2006) 2.00
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA (2006) 2.00
Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens (2010) 2.00